A meta-analysis of placebo-controlled RCT involving adult individuals with NAFLD suggests that SGLT-2 inhibitors cause a remarkable improvement in hepatic enzymes and also diminish liver fat content [5]. Nasiri-Ansari et al. [37] discovered that, after five weeks of treatment with EMPA, apolipoprotein E (ApoE) (-/-) mice had reduced expression of six key enzymes involved in the fatty acid synthesis. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.